- Initial quantity delivered to 슬롯사이트 Corporation, with supply set to expand nationwide through dealerships by end of March
- Administration is expected to expand in April based on veterinarian prescriptions at frontline animal hospitals
- 슬롯사이트15 immune anticancer effect to be revealed at the 2025 Seoul Veterinary Spring Clinical Conference
- 슬롯사이트 to present research and academic findings, Yuhan Corporation to pursue a two-track strategy of promotion and marketing
[by Kang, In Hyo] Vaxcellbio, a company specializing in anticancer immunotherapy drug development, announced on March 17 the official launch of ‘슬롯사이트15,’ the first Korean immunotherapy drug for companion animals, scheduled for release this week.
Vaxcellbio recently provided the initial batch of 슬롯사이트15 to Yuhan Corporation, which plans to distribute the secured supply through animal pharmaceutical dealers across the country starting in late March. Accordingly, prescriptions and administration of 슬롯사이트15 are expected to be available at frontline animal hospitals beginning in April.
In a clinical trial involving dogs that underwent mammary tumor resection surgery, 슬롯사이트15 demonstrated a significant improvement in clinical symptoms and quality of life compared to the control group, which only received tumor removal surgery. The treatment also exhibited minimal side effects, with its safety confirmed through physical examinations and hematological tests.
In the future, Vaxcellbio will continue its follow-up research and academic presentations to widely publicize the immunotherapy effects of 슬롯사이트15. A two-track strategy will be employed, with Yuhan Corporation overseeing promotion and marketing efforts. Notably, at the '2025 Seoul Veterinary Spring Clinical Conference' on March 29 and 30, Vaxcellbio will present the immune anticancer effects of 슬롯사이트15. Additionally, Yuhan Corporation will operate a promotional booth and conduct full-scale marketing initiatives.
Vaxcellbio is expanding the indications of 슬롯사이트15 from canine mammary tumors to lymphoma and is also working on extending its use to diseases in companion cats. For lymphoma, the company has confirmed the drug’s efficacy and safety through clinical trials and has submitted a product approval application to the Animal and Plant Quarantine Agency (APQA).
"We plan to file patent applications for technologies that enhance convenience by diversifying the administration route while broadening the indications of 슬롯사이트15 to treat various cancers," said Lee Je-jung, CEO of Vaxcellbio. "We are developing export strategy modules tailored to each continent to expand 슬롯사이트15’s sales channels beyond the Korean market."
On the other hand, according to market research firm Grand View Research, the global pet anticancer 슬롯사이트 market is projected to grow from approximately USD 1.18 billion in 2023 to around USD 2.49 billion by 2030, reflecting an average annual growth rate of 11.29%.
However, according to Vaxcellbio, no product has yet been approved as a companion canine lymphoma immunotherapy in the global market. The company anticipates that if 슬롯사이트15 becomes the world's first canine lymphoma immunotherapy to receive approval, it will create significant momentum for entering the global companion pet anticancer drug market.